Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice

• Published in: Journal of biomedical science Vol. 16; no. 1; p. 47
• Main Authors: Yiang, Giou-Teng, Harn, Horng-Jyh, Yu, Yung-Luen, Hu, Sheng-Chuan, Hung, Yu-Ting, Hsieh, Chia-Jung, Lin, Shinn-Zong, Wei, Chyou-Wei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.05.2009; BioMed Central; BMC
• Subjects: Adenoviridae; Adenovirus; Animals; Cell Line, Tumor; Dependovirus - genetics; Dependovirus - metabolism; Female; Genetic Therapy; Genetic Vectors - genetics; HeLa Cells; Humans; Immunotherapy; Interleukin-15 - genetics; Interleukin-15 - metabolism; Mice; Mice, Nude; Neoplasms - metabolism; Neoplasms - therapy
• ISSN: 1423-0127; 1021-7770; 1423-0127
• DOI: 10.1186/1423-0127-16-47

Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.